PDCD1 and non-small cell lung carcinoma: Immunotherapy has reached center stage in the field of second-line therapy in oncology treatment, and anti-PD-1 therapy has shown objective responses in variety of human malignancies, including melanoma, non-small cell lung cancer and renal cell carcinoma [2].